Mark L. Baum
Member, Board of Directors
Mr. Baum is a founder, board member and CEO of Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY). Beginning in 2011, Mr. Baum led the restructuring and reorganization of Imprimis,
including raising nearly $25M in new equity capital to support building Imprimis’ novel pharmaceutical innovation and distribution business. Prior to Mr. Baum’s involvement with Imprimis, from 2001 to 2011, he was the founder and managing director of California-based TBLF, LLC, where he managed a series of three funds, acting as a principal investor primarily in financing publicly traded companies or bridge-to-public-equity transactions. Before his fund management experience, in 1999, Mr. Baum founded and served as the president of YesRx, a publicly traded Los-Angeles-based closed-door pharmacy business. In 1998, after graduating from law school, Mr. Baum founded The Baum Law Firm, P.C. where he focused his practice on US securities laws, reporting requirements and public company finance-related issues that affect small capitalization public companies. Throughout his career, Mr. Baum has actively participated in numerous public company spin-offs, restructurings and recapitalizations, venture fundings, private-to-public mergers, asset acquisitions and divestitures. In addition to his experience financing, operating and advising small capitalization publicly-traded enterprises, Mr. Baum serves on the board of directors for Ideal Power, Inc. (NASDAQ: IPWR) where he is also chairman of the audit committee. Mr. Baum is also the chairman of the board of directors of Endra, Inc., a privately-held Ann Arbor, Michigan-based medical imaging company. Mr. Baum is a published inventor and is an inactive member of both the State Bar of California and the State Bar of Texas.
Andrew R. Boll
Mr. Boll has been the Vice-President of Accounting and Public Reporting of Imprimis Pharmaceuticals since February 2012, and was a consultant to the Company from December 2011 up to his hire date.
Before joining Imprimis, from 2007 to 2011, Mr. Boll was an accountant for BCGU, LLC, a privately-held fund manager, and its related entities, that specialized in capital venture-type investment opportunities. While at BCGU, he provided CFO/Controller consulting services to public company clients, compiling numerous SEC financial reports, and participating in several public company restructurings, financings and private to public mergers. From 2004 to 2007, Mr. Boll held various accounting roles at Welsh Companies, LLC, a privately held commercial real estate company, its fund and its other subsidiaries. Mr. Boll is a CFA charterholder, a Certified Management Accountant and received his B.S. degree in Corporate and Public Finance, summa cum laude, from Huron University. He is also a member of the Institute of Management Accountants, the CFA Institute, and the CFA Society of San Diego.
Mr. Seelhorst, has over 17 years of clinical and corporate development experience with both large-cap pharmaceutical companies (e.g. Eli Lilly and Pfizer) as well as start-up ventures including extensive capital raising, licensing, and M&A transactions.
Most recently, Gary has worked as a management consultant for several start-ups both raising capital and setting up strategic joint ventures in both the pharmaceutical and nanotechnology spaces. In 2012, he worked for HUYA Biosciences International in Global Business Development setting up both in-licensing and strategic partnerships primarily in China. From 2006 to 2011, he worked as VP of Business Development and Strategic Marketing for Naviscan, a medical device and biotech start-up wherein he helped to build up both the commercial side of the business as well as execute many in- and out-licensing deals which lead to some significant partnerships with Fortune 500 companies, i.e. Johnson & Johnson, Hologic, and CR Bard. From 1998 to 2006, Gary worked at Pfizer in various positions in Clinical Development as well as Corporate Development, helping to initiate a burgeoning in-licensing and M&A campaign which resulted in several large M&A transactions. From 1996 to 1998, Gary worked as a Medical Writer for Eli Lilly with his entire tenure devoted to writing a successfully approved NDA for Prozac®. Gary received an MBA from the University of Michigan, an MS from Indiana University, and a Bachelor’s degree from the University of California at San Diego.
Victor Repkin, Ph.D., has served as patent attorney and intellectual property analyst for Imprimis Pharmaceuticals since June 2013. Dr. Repkin has more than 15 years of experience in patent preparation and prosecution, patent counseling and due diligence.
He has extensive experience drafting and prosecuting patents in synthetic organic chemistry, polymer chemistry, pharmaceuticals, and protein and enzyme technologies. Dr. Repkin has drafted or prosecuted over 170 issued patents and hundreds more pending patent applications, and has coordinated prosecution and enforcement in the US and worldwide for therapeutics developed by pharmaceutical, biotechnology and medical device companies. In addition, Dr. Repkin has an extensive background as a research chemist. From 1985 through 1993, he held a variety of research positions, including senior research chemist, with E.I. DuPont de Nemours and Co., Wacker Silicones Corp. and Pigment Co. Dr. Repkin received his B.S. and M.S. in Chemistry and Chemical Engineering and his Ph.D. in Polymer and Organic Chemistry from Leningrad Institute of Technology and his J.D. from Thomas Jefferson School of Law.
Mr. Saharek is an experienced ophthalmology industry leader with a 30 year track record of building high performing commercial teams, developing and executing strategic plans, building brands, launching products and delivering outstanding results for a variety of healthcare companies.
Over the past 15 years he has been focused in the ophthalmology segment where he has established valuable clinical relationships with key opinion leaders in the Refractive, Cataract and Retina subspecialties. Prior to joining Imprimis in November 2012, he most recently served as Head of U.S. Marketing and Strategy for ThromboGenics Inc., developing the commercialization strategy and building the field team to launch a new biologic in the US. Prior to that he was Vice President, Business Development at SurModics Inc., after spending six years managing sales and marketing for cataract and vitreoretinal surgical and drug products for Bausch & Lomb. Mr. Saharek began his career in the diagnostics industry at Boehringer Mannheim.